Sagimet Biosciences INC 8-K filings

Sagimet Biosciences reported statistically significant positive results from its Phase 2b FASCINATE-2 clinical trial of denifanstat for treating metabolic dysfunction-associated steatohepatitis (MASH), showing improvements in liver fibrosis and other key endpoints.

Sagimet Biosciences has released an investor presentation highlighting positive clinical trial results for its drug candidate, denifanstat, in MASH, acne, and cancer, along with a strong financial position.

Sagimet Biosciences announced positive results from its Phase 2b clinical trial for denifanstat in MASH and secured $104.7 million in funding, positioning the company to advance to a Phase 3 trial.

Sagimet Biosciences has appointed Thierry Chauche as its new Chief Financial Officer, effective May 6, 2024, replacing interim CFO Joseph Oriti.

Sagimet Biosciences announced the expansion of its board of directors, positive results from a Phase 2b trial for its MASH treatment, and a successful follow-on offering, extending its cash runway through 2025.

Sagimet Biosciences has appointed Joseph Oriti as Interim Principal Financial Officer and Interim Principal Accounting Officer, effective February 1, 2024, following the resignation of Anthony Rimac.

Sagimet Biosciences successfully priced a public offering of 9 million shares at $12.50 per share, raising $112.5 million to fund its clinical programs.

Sagimet Biosciences estimates its cash, cash equivalents, and short-term investments were approximately $94.9 million as of December 31, 2023.

Sagimet Biosciences' denifanstat demonstrated statistically significant improvements in NASH resolution and fibrosis reduction in a Phase 2b clinical trial.